Ficus hirta Vahl. ameliorates liver fibrosis by triggering hepatic stellate cell ferroptosis through GSH/GPX4 pathway

• Published in: Journal of ethnopharmacology Vol. 334; p. 118557
• Main Authors: Yang, Yuxuan, Chen, Yanchun, Feng, Dongge, Wu, Huixing, Long, Changrui, Zhang, Jianping, Wang, Jinghao, Zhou, Benjie, Li, Shasha, Xiang, Shijian
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 15.11.2024
• Subjects: Apigenin; Ficus hirta vahl; GSH/GPX4 pathway; Liver fibrosis; GSH/GPX4 pathway; Liver fibrosis; Apigenin; Ficus hirta vahl
• ISSN: 0378-8741; 1872-7573; 1872-7573
• DOI: 10.1016/j.jep.2024.118557

Ficus hirta Vahl., a traditional Chinese medicine commonly used in the Lingnan region, has been extensively used for liver disease treatment in China. Its notable antioxidant and anti-inflammatory properties have been reported in previous studies. However, its potential effect and underlying mechanism on liver fibrosis remains unclear. This study was aimed to investigate the effect and its underlying mechanism of Ficus hirta Vahl on liver fibrosis in vitro and in vivo. The main components of Ficus hirta Vahl in blood were investigated by using UPLC-Q/TOF-MS/MS. Two animal models of liver fibrosis, the CCl4 and MCD induced mice, were used to assess the efficacy of Ficus hirta Vahl on liver fibrosis. Metabolomics was used to detect the level of metabolites in the serum of liver fibrosis mice after Ficus hirta Vahl treatment. Furthermore, the mechanism was validated in vitro using the human liver stellate cell line LX-2. The binding affinities of the active ingredients of Ficus hirta Vahl to the main targets of liver fibrosis were also determined. Finally, we identified the key active ingredients responsible for the treatment of liver fibrosis in vivo. Fibrosis and inflammatory markers were significant down-regulation in both CCl4 and MCD induced liver fibrosis mice after Ficus hirta Vahl administration in a dose-dependent manner. We found that Ficus hirta Vahl may primarily exert its effect on liver fibrosis through the glutathione metabolic pathway. Importantly, the glutathione metabolic pathway is closely associated with ferroptosis, and our subsequent in vitro experiments provided evidence supporting this association. Ficus hirta Vahl was found to modulate the GSH/GPX4 pathway, ultimately leading to the amelioration of liver fibrosis. Moreover, using serum pharmacochemistry and molecular docking, we successfully identified apigenin as a probable efficacious monomer for the management of liver fibrosis and subsequently validated its efficacy in mice with CCl4-induced hepatic fibrosis. Ficus hirta Vahl triggered the ferroptosis of hepatic stellate cell by regulating the GSH/GPX4 pathway, thereby alleviating liver fibrosis in mice. Moreover, apigenin is a key compound in Ficus hirta Vahl responsible for the effective treatment of liver fibrosis. FV triggers the ferroptosis of hepatic stellate cell to ameliorate liver fibrosis by regulating the GSH/GPX4 pathway. Moreover, apigenin is the key compound in FV responsible for the effective treatment of liver fibrosis. [Display omitted] •The anti-liver fibrosis mechanism of action of Ficus hirta Vahl was evaluated.•Ficus hirta vahl triggers the ferroptosis of hepatic stellate cell through GSH/GPX4 pathway.•Apigenin is the active ingredient in FV for the treatment of liver fibrosis.